Cargando…

Severe Ulcerative Esophagitis Induced by Crizotinib Therapy

Crizotinib is an oral tyrosine-kinase inhibitor that inhibits anaplastic lymphoma kinase (ALK) in gene-rearranged non-small cell lung cancer (NSCLC). In 2011, the Food and Drug Administration approved crizotinib for treatment of locally advanced or metastatic ALK-positive NSCLC. The crizotinib adver...

Descripción completa

Detalles Bibliográficos
Autores principales: Jalil, Ala' A Abdel, Craig, Jamie, Bajaj, Rajesh, Spurling, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Gastroenterology 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435292/
https://www.ncbi.nlm.nih.gov/pubmed/26157832
http://dx.doi.org/10.14309/crj.2014.8
_version_ 1782371893114830848
author Jalil, Ala' A Abdel
Craig, Jamie
Bajaj, Rajesh
Spurling, Timothy
author_facet Jalil, Ala' A Abdel
Craig, Jamie
Bajaj, Rajesh
Spurling, Timothy
author_sort Jalil, Ala' A Abdel
collection PubMed
description Crizotinib is an oral tyrosine-kinase inhibitor that inhibits anaplastic lymphoma kinase (ALK) in gene-rearranged non-small cell lung cancer (NSCLC). In 2011, the Food and Drug Administration approved crizotinib for treatment of locally advanced or metastatic ALK-positive NSCLC. The crizotinib adverse events profile included esophageal disorders in 11% of patients treated during trial phases I, II, and III, but none of them had severe events. We describe the development of severe ulcerative esophagitis secondary to crizotinib therapy and the re-introduction of therapy at a lower dose without recurrence of esophageal symptoms.
format Online
Article
Text
id pubmed-4435292
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher American College of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-44352922015-07-08 Severe Ulcerative Esophagitis Induced by Crizotinib Therapy Jalil, Ala' A Abdel Craig, Jamie Bajaj, Rajesh Spurling, Timothy ACG Case Rep J Case Report Crizotinib is an oral tyrosine-kinase inhibitor that inhibits anaplastic lymphoma kinase (ALK) in gene-rearranged non-small cell lung cancer (NSCLC). In 2011, the Food and Drug Administration approved crizotinib for treatment of locally advanced or metastatic ALK-positive NSCLC. The crizotinib adverse events profile included esophageal disorders in 11% of patients treated during trial phases I, II, and III, but none of them had severe events. We describe the development of severe ulcerative esophagitis secondary to crizotinib therapy and the re-introduction of therapy at a lower dose without recurrence of esophageal symptoms. American College of Gastroenterology 2014-01-10 /pmc/articles/PMC4435292/ /pubmed/26157832 http://dx.doi.org/10.14309/crj.2014.8 Text en Copyright © Abdel Jalil et al. This is an open-access article. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Case Report
Jalil, Ala' A Abdel
Craig, Jamie
Bajaj, Rajesh
Spurling, Timothy
Severe Ulcerative Esophagitis Induced by Crizotinib Therapy
title Severe Ulcerative Esophagitis Induced by Crizotinib Therapy
title_full Severe Ulcerative Esophagitis Induced by Crizotinib Therapy
title_fullStr Severe Ulcerative Esophagitis Induced by Crizotinib Therapy
title_full_unstemmed Severe Ulcerative Esophagitis Induced by Crizotinib Therapy
title_short Severe Ulcerative Esophagitis Induced by Crizotinib Therapy
title_sort severe ulcerative esophagitis induced by crizotinib therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435292/
https://www.ncbi.nlm.nih.gov/pubmed/26157832
http://dx.doi.org/10.14309/crj.2014.8
work_keys_str_mv AT jalilalaaabdel severeulcerativeesophagitisinducedbycrizotinibtherapy
AT craigjamie severeulcerativeesophagitisinducedbycrizotinibtherapy
AT bajajrajesh severeulcerativeesophagitisinducedbycrizotinibtherapy
AT spurlingtimothy severeulcerativeesophagitisinducedbycrizotinibtherapy